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Abstract 
Background: It is well known that antibiotic use is the main driver for the increasing 
problems with resistant bacteria. Consequently, some countries have recommended 
shortening the duration of antibiotic treatment of community-acquired pneumonia 
(CAP). The aim of this study was to investigate if the effectiveness of a short-course 
antibiotic is comparable to a longer course of antibiotics in adults with CAP and to 
assess if the duration of an antibiotic course influences the development of resistant 
bacteria.  
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Methods: A literature search was performed in PubMed and EMBASE. We included 
randomised, controlled trials (RCTs) comparing clinical success, microbiological 
efficacy, patient safety and antibiotic resistance in a short-course (5 days) versus a 
long-course antibiotic treatment (7+ days) for CAP. 
Results: Six RCTs were included. Clinical success rates were 87-95% in patients 
treated with short-course antibiotics and 88-94% in patients treated with a longer 
course. Eradication of pathogenic bacteria was found to be 100% and 95-100% in 
patients treated with short-course and long-course antibiotics, respectively.  
No significant differences in adverse events were reported. However, none of the trials 
reported on the impact on the development of resistant bacteria.  
Conclusion: Only few trials were included in this review and more RCTs are highly 
needed to be able to provide solid evidence for optimal treatment durations for 
patients diagnosed with CAP. Importantly, fluoroquinolones were often the drug of 
choice, and trials testing beta-lactam antibiotics, which are the type of antibiotics most 
often used in many European countries, should be aimed for in near future.   
 
Introduction 
Antibiotics are one of the most commonly used drugs worldwide (1). It has long been 
acknowledged that consumption of any antibiotic generates unwanted adverse events, 
like antibiotic resistance. The higher the consumption of antibiotics, the greater the 
risk of selection of resistant bacteria (2). According to a recent report by O'Neill 2016, 
in the year 2050, the number of deaths due to infections caused by resistant bacteria 
will reach 10 million lives each year (3). Following this, modern medicine can be set 
back to a time where simple infections again will be lethal. 
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Around 90% of antibiotics are prescribed in primary care (4), thus making general 
practice a crucial area for interventions aimed at reducing unnecessary use of 
antibiotics.  
In general practice, most lower respiratory tract infections (LRTI) are mild and require 
no antibiotic treatment. In fact, only about 13% of patients with the diagnosis of 
pneumonia in general practice have a radiologically verifiable pneumonia (5).  
Furthermore, many patients are recommended to complete an antibiotic treatment 
even if their symptoms have resolved; the rationale behind these recommendations 
are not evidence-based, but mainly based on traditions (1, 6).  
Use, misuse and overuse of antibiotics are the main drivers for the selection of 
resistance bacteria. Reduced prescribing rate and shorter duration of an antibiotic 
course can reduce exposure to antibiotics and hereby curbing antibiotic resistance. 
The duration of antibiotic treatment of community-acquired pneumonia (CAP) has 
long been discussed in the scientific community due to lacking evidence of the current 
regimen, i.e. 7-10 days of treatment. Consequently, several studies have recently been 
conducted to investigate the effects of a shorter duration of antibiotic treatment. 
The aim of this review was to investigate if the effectiveness of a short-course 
antibiotic is comparable to a longer course of antibiotics in adults with CAP, and to 
assess if the duration of an antibiotic course will influence the development of resistant 
bacteria.  
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Materials and Methods 
Literature search 
A literature search was performed to identify randomised, controlled trials comparing 
short- versus long-course antibiotic treatments for CAP. Trials published before 23 
April 2018 in English were identified in PubMed and EMBASE. The search was based 
on the following terms: “community-acquired pneumonia”, the MeSH term 
“community-acquired infections” with the following subheadings: “therapy” and “drug 
therapy” and a combination of the following words: antibiotic*, short/shorter-course, 
long/longer-course, duration and antibiotic duration. A complete search string is 
available from the authors on request. 
        
Selection of articles 
Only randomised, controlled trials were included. A trial was considered eligible for 
inclusion if it (i) included adults (18+ years) diagnosed with CAP, (ii) compared a 
short-course antibiotic treatment with a longer course, and (iii) if patients exclusively 
were treated at outpatient clinics. 
Furthermore, the following exclusion criteria were applied: (i) studies testing individualised 
treatment, and (ii) studies including patients with comorbidity such as chronic lung disease or 
lung cancer. 
Outcome measures 
A short-course antibiotic treatment was defined as 5 days of treatment and a long-
course antibiotic treatment was defined as 7+ days of treatment. 
The following outcomes were reported: 
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1. Clinical success, defined as if clinical symptoms and signs associated with the 
pneumonia were resolved. 
2. Microbiological efficacy, defined as decrease pre-treatment compared to post-
treatment, in the amount of bacterial colonies or eradication of bacterial cultures. 
3. Patient safety, defined as the reporting of adverse events, which were classified as 
either related, possibly related or unrelated, and/or mild, moderate or severe. 
4. Development of resistant bacteria (any reporting on resistant bacteria). 
 
Quality assessment  
The quality of the included randomised, controlled trials was assessed by the Jadad 
criteria (7). The trials were evaluated in seven items, the first five items can obtain +1 
point and the last 2 items can be given -1 point, which makes the highest score in a 
total of five the best assessment (Table 4). The points were awarded for 
randomisation, blinding, description of withdrawals and dropouts. 
 
Results 
Study characteristics 
The searches in PubMed and EMBASE resulted in 276 and 19 potential studies, 
respectively. Most trials (N = 125) were excluded as they compared the effects of 
different types of antibiotics, 38 trials were excluded because they included children, 
and an additional 29 trials were excluded as they were not about CAP. 
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Six studies were included in this literature review. The selection process is described 
in detail in Fig. 1.  
Four of the included trials randomised the population right from the start of the trial 
(9, 10, 11, 13), and two studies did not randomise the study population until after five 
days of treatment, and only if a treatment effect was observed (8, 12) (Table 1). 
Table 2 presents an overview of all study results from the six included trials. 
 
Type and dose of antibiotics 
The included studies tested various antibiotics such as levofloxacin, gemifloxacin, 
amoxicillin and cefuroxime. Three trials used different doses of antibiotics in the short- 
and long-course treatment groups, respectively, with the highest dose of antibiotics 
used in the short-course treatment groups (9, 10, 13). In another two studies, the 
short-course treatment group and long-course treatment group received the same 
dose of antibiotics (11, 12). In the study by Uranga et al., it was only stated that 
antibiotic treatments were according to local guidelines; consequently, it is unknown 
what type of antibiotic was used, and in which doses they were prescribed (8). 
Clinical success 
In the three studies using different dosage of antibiotics but same type of antibiotic, 
750 mg levofloxacin short-course regimen (5 days) versus 500 mg levofloxacin 
(median 10 days), all had high clinical success rates and there was no statistically 
significant difference between the two groups. The clinical success rates were 90-94% 
in patients treated with short-course levofloxacin and 91-96% in patients treated with 
long-course levofloxacin (9, 10, 13).  
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In the three studies, where the intervention group and control group received the same 
dose of antibiotics, there were likewise a high clinical success rate with no statistically 
significant difference between the short-course and long-course treatment groups. The 
clinical success rates were 88-95% in patients treated with short-course antibiotics 
and 88-92% in patients treated with long-course antibiotics (11, 12).  
In the study by Uranga et al. (2016), in which the local guidelines determined the dose 
of antibiotic, the clinical success rate at follow-up was 92.7% and 94.4%, respectively, 
in the short-course treatment group (5 days) and long-course treatment group 
(median 10 days) (p=0,54)(8). 
Overall, a clinical success rate of 91-94% was observed when antibiotics were given for 
7-14 days (long-course). Similarly, a clinical success rate of 86.9-95.0% was observed 
when antibiotic courses were prescribed for 5 days (short-course).  
 
Microbiological efficacy 
Table 3 provides an overview of pathogens identified in patients diagnosed with CAP 
in the six included trials. Three studies included the microbiological eradication as a 
secondary efficacy parameter (9, 10, 11). The microbiological efficacy was based on the 
results of cultures taken pre- and post-treatment. Zhao, T. (2016) and Zhao, X. (2014) 
found a bacterial eradication rate of 100% in both the short-course and long-course 
treatment groups (9, 10). File et al. (2007) examined the eradication rates of 
Streptococcus pneumoniae and identified a small non-significant difference in the 
eradication efficacy rate at follow-up, with 100% for those treated for 5 days (short-
course) and 95% for those treated with antibiotics for 7+ days (long-course)(11), 
(Table 2).   
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Patient safety evaluation  
All six studies reported on patient safety outcomes (Table 2).  
In the studies by Uranga et al. (2016) and Dunbar et al. (2003), no significant 
differences in adverse events were observed between the groups by day 30 (8, 13). In 
one study, 55% of patients had experienced an adverse event in the 750-mg 
levofloxacin group (short-course), and 49% of patients had reported an adverse events 
in the 500-mg levofloxacin group (long-course)(10). These adverse events were 
considered drug-related but with no significant difference (10). One study showed that 
the incidence of adverse events was low and the proportion of discontinuations due to 
adverse events was 1.2% and 2% for the short-course and long-course treatment 
groups, respectively (11). In the study by El Moussaoui et al. (2006), 11% in the short-
course treatment group compared with 21% in the long-course treatment group 
reported mild adverse events during or at the end of treatment periods (12) (Table 2). 
Of the five studies reporting on adverse events, none of them demonstrated 
statistically significant differences in the number of adverse events, whether 
antibiotics were given for a shorter or longer period.  
 
Antibiotic resistance 
None of the included trials reported on the impact of the duration of an antibiotic 
course on the development of resistant bacteria (9, 10, 11, 12, 13).  
Jadad score 
The quality of the included trials varied and ranged from two to four in Jadad score - a 
detailed overview of the quality assessments is available in Table 4.  
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Three points were given to three of the studies (8, 9, 11), one trial obtained two points 
(10) and the rest obtained four points (12, 13). All of the included studies obtained 
points for being a randomised, controlled trial and for the description of withdrawal. 
None of the studies were deducted a point for inappropriate randomisation or 
blinding. 
 
Discussion 
Main findings 
Adults treated for CAP had similar clinical cure rates when given a short-course of 
antibiotics (5 days) compared to those receiving a longer course (7+ days). Also, 
almost identical bacterial eradication rates were demonstrated regardless of treatment 
duration, and no difference in the reporting of adverse events was found. Importantly, 
there was an absence of evidence on the impact of treatment duration on the 
development of antibiotic resistance.  
 
Strengths and limitations 
This literature review has summarised the evidence from the relatively few trials 
reporting on short- versus long-course antibiotic treatment for CAP. The included trials 
differ in certain aspects (Table 1 and 5). The differences include various randomisation 
procedures, diverse study populations, dispersed geographical locations, different 
types of antibiotics used and various definitions of short-course and long-course 
treatment. 
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 Only six randomised, controlled trials were included in this review and the risk of a 
type 2 error, i.e. rejecting that there is a difference between choosing a shorter 
treatment period compared to a longer treatment period is present. This possible 
difference in effectiveness between the treatment duration is important to identify due 
to the risk of severe complications associated with CAP. With this in mind, more trials 
testing optimal treatment durations are highly needed to be able to provide solid 
evidence for optimal treatment durations for patients diagnosed with CAP.  
Several other limitations have to be kept in mind when interpreting the results of this 
literature review. Firstly, none of the included trials provided any information about 
the effect of the duration of the antibiotic courses on the development of resistant 
bacteria. Consequently, we were not able to report on this outcome, however, it seems 
plausible that by minimising the days of antibiotic treatment,  the risk of antimicrobial 
resistance can be reduced. 
Secondly, none of the included trials provided sufficient data to report on the 
comparative effectiveness of short- versus long-courses of antibiotics for rare outcomes 
associated with CAP, such as hospitalisation or deaths. 
Furthermore, the various treatment durations were not assessed in accordance with 
the severity of the infections (mild, moderate, severe), or perhaps more importantly 
the aetiology of the pneumonia. For example, pneumonia caused by Legionella 
pneumophila is recommended antibiotic treatment for two to three weeks, compared 
with seven days for pneumonia caused by Streptococcus pneumonia (14). 
 
Some of the included trials used different doses of antibiotic, with a higher dosage in 
the short-course duration group compared with the dosage in the long-course duration 
group. This decreases internal comparability in this review, and instead raises the 
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question whether it is the duration or total amount of antibiotics that matter to the 
success rate.  
Fluoroquinolones were used as treatment regimens in five out of six of the included 
RCTs (Urange 2016, Zhao 2016, Zhao 2014, File 2007 and Dunbar 2003). Only one 
study used amoxicillin (El Moussaoui 2006). Consequently, the results from this 
literature review cannot be generalised to a Danish setting, nor to many other 
European countries in which fluoroquinolones are seldom used for treatment of 
patients with CAP. 
 
In one study, patients were first treated with intravenous treatment, in contrast to a 
complete oral course (El Moussaoui 2006). This approach is not usual care in most 
general practices and consequently influences the generalisability of these findings.  
 
The quality of the included trials was moderate with Jadad scores of two to four, 
primarily three. However, this score only indicates something about the 
methodological quality of the trials and nothing about generalisability or the quality of 
the results in the included studies. For example, most studies were conducted in 
middle- and high-income countries and with great variation in the study population. 
There were few data on comparative effectiveness of short and long courses of 
antibiotics in low-income countries, where baseline risks, immunization rates, 
complication rates and access to antibiotic treatment may differ substantially from 
middle- or high-income countries.  
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Comparison with other studies 
In the fight against the increasing problems with resistant bacteria, the optimal length 
of antibiotic treatment for CAP is being massively investigated these years (15, 16, 17). 
A meta-analysis from 2007 found no significant differences between short-course (5 
days) and long-course (7+ days) antibiotic regimens for the treatment of mild to 
moderate CAP with respect to clinical success, mortality, bacteriological success and 
adverse events (15). A more recent review from 2017 showed similar clinical cure 
rates when given shorter courses of antibiotics compared to those receiving longer 
courses. In this review, a shorter course of antibiotics was also associated with lower 
rates of adverse events than longer courses of antibiotic (16). This present literature 
review did not include children, however, a study by Agarwal G. et al. (2004) 
demonstrated equivalent efficacy of three days versus five days of antibiotic treatment 
of pneumonia in children (17). 
Importantly, a newly published review from 2018 by López-Alcalde J. et al. did not 
identify any randomised, controlled trials studying a short course of antibiotic 
compared to a longer course, with the same type of antibiotic and with the same daily 
dosage, for CAP in adult outpatients (18). 
 
Conclusion  
Despite the above-mentioned differences in the designs of the included studies and the 
limitations of this literature review, all of the included trials demonstrated a similar clinical 
effect in patients treated with either a short or long antibiotic course. However, only six 
trials were included and more trials investigating the optimal antibiotic treatment duration 
of CAP are warranted. Preferably, these trials should compare treatments with the same 
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type of antibiotic, and same dose, and test antibiotics commonly used in most European 
countries (e.g. phenoxymethylpenicillin or amoxicillin). Also, these trials should involve 
both children and adults and importantly not only focus on efficacy outcomes, but also on 
adverse events including the development of resistant bacteria. 
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Appendix 
Figure 1 – Study selection process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through database searching in 
PubMed 
 
 (n = 4408) 
Additional records identified through database 
searching in Embase 
 
(n = 8719) 
 
n = 295 
 
n = 6 
Records excluded based on 
these limitations: Randomised, 
clinical trial and publications in 
English 
(n = 4132) 
Records excluded based on these 
limitations: Randomised, 
controlled trial, publications in 
English, humans and excluding 
Medline journals. 
 (n = 8700) 
 
n = 276 
 
n = 19 
Records excluded (n = 289) due to: 
- Individualised treatment (n = 2) 
- Comparison of the effect of different types of antibiotics (n = 125) 
- Children (n = 38) 
- Effect of procalcitonin (n = 15) 
- Disease other then CAP (n = 29) 
- Other medicines than antibiotics (n = 16) 
- Economic focus (n = 10) 
- Patients with comorbidity (n = 3) 
- Focus on diagnosis (n = 11) 
- Prediction of long-term outcome (n = 9) 
- Side effects of treatment (n = 1) 
- Focus on when there is response to treatment (n = 1) 
-How long intravenous treatment should be given (n = 8) 
- Non-medical treatment (n = 4) 
- Guidelines (n = 6) 
- Factors leading to hospitalization (n = 4) 
- Retrospective analyse (n = 2) 
- Focus on ventilation (n = 2) 
- Aetiology of CAP (n =  3) 
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Table 1 – Study design of included studies 
 
Study (year) Country Population Method Type of 
antibiotics 
Duration of 
long treatment 
Duration of 
short 
treatment 
Uranga A et al. 
(2016) (8) 
Spain 283 patients, 
137 in control 
group and 146 
in intervention 
group. 
RCT, starts with 
oral treatment, 
if there were 
effect after 5 
days, they were 
randomised for 
long or short 
course 
treatment. 
According to 
local guidelines. 
80% underwent 
treatment with 
quinolones. 
 
- Unknown if it 
is the same 
dose of drug in 
the two groups.  
Physicians, 
determined 
duration of 
antibiotics in 
the control 
group.  
Median 10 days 
5 days 
Zhao T et al. 
(2016) (9) 
China 427 patients, 
219 in control 
group and 208 
in intervention 
group. 
RCT, starts by 
randomisering 
patients for a 
long or short 
course 
treatment. 
Levofloxacin 
 
- 750 mg in the 
intervention 
group and 500 
mg in the 
control group. 
7-14 days. 
Median 10.35 
days 
 
5 days 
Zhao X et al. China 211 patients, 
104 in control 
RCT, starts by 
randomisering 
Levofloxacin 7-14 days 5 days 
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(2014) (10) group and 107 
in intervention 
group. 
patients for a 
long or short 
course 
treatment. 
 
- 750 mg in the 
intervention 
group and 500 
mg in the 
control group. 
File TM et al. 
(2007) (11) 
9 countries: 
Bulgaria, 
Croatia, Czech 
Republic, 
Lithuania, 
Poland, 
Romania, 
Russia, Ukraine 
and the USA. 
469 patients, 
227 in control 
group and 242 
in intervention 
group. 
RCT, starts by 
randomisering 
patients for a 
long or short 
course 
treatment. 
Gemifloxacin 
 
- Same dose of 
drug in the two 
groups 
7 days 5 days 
El Moussaoui  
R et al. (2006) 
(12) 
Netherlands 96 patients, 49 
in control 
group and 47 in 
intervention 
group. 
RCT, starts with 
intravenous 
treatment end 
shift to oral, if 
there were 
effect of the 
treatment, 
patients were 
randomised to 
short or long 
course 
treatment. 
Amoxicillin 
 
- Same dose of 
drug in the two 
groups 
10 days 5 days 
Dunbar LM et United State of 390 patients, 
192 in control 
RCT, starts by 
randomisering 
Levofloxacin 10 days 5 days 
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al. (2003) (13) America group and 198 
in intervention 
group. 
patients for a 
long or short 
course 
treatment. 
 
- 750 mg in the 
intervention 
group and 500 
mg in the 
control group. 
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Table 2 – Overview of study results  
Study 
(year) 
Clinical success – at follow-up Bacterial 
eradication 
Adverse events Other results 
 Intervent
ion group 
Control 
group 
P-value CI-95% Interventi
on group 
Control 
group 
Intervent
ion 
group 
Control 
group 
 
Uranga A et 
al. (2016) 
(8) 
92.7% 94.4% 0,54 - - - 17% 18% 
P = 
0,24 
The CAP symptom 
questionnaire scores on 
day 10: 18.1 and 17.6 in 
the control and 
intervention groups, 
respectively, P= .81. 
Zhao T et al. 
(2016) (9) 
93.75% 95.98% 0,35 0.269 – 
1,537 
 
100.0% 100.0% 15,35% 10,48% 
P < 
0,05 
The mean drug exposure 
was 3,641.4 mg in 
intervention group and 
5,169.6 mg in control 
group. P<0.0001.  
Zhao X et al. 
(2014) (10) 
89,9% 91,9% - -13,9 – 
12,3 
100.0% 100.0% 22,3% 22,5% 
P > 
0,05 
- 
File TM et 
al. (2007) 
(11) 
95,0% 92,1% 0,2 -1,48 – 
7,42 
100% 95% 1,2% 2% - 
El 
Moussaoui  
R et al. 
(2006) (12) 
90% 88% - -9 - 15 - - 11% 21% - 
Dunbar LM 
et al. (2003) 
(13) 
92,4% 91,1% - -7,0 – 
4,4 
- - 57,8% 59,6% 
 
 
By day 3 of therapy, 
67.4% in intervention 
group reported subjective 
resolution of fever, 
compared with 54.6% in 
control group.           P 
=.006.  
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Table 3 – Article overview of pathogens in included trials 
Study (year) Pathogen Evaluable (n) Eradicated 
Uranga A et al. 
(2016) (8) 
Unknown   
Zhao T et al. 
(2016) (9) 
Unknown   
Zhao X et al. 
(2014) (10) 
Gram-positive 
- S. pneumoniae 
- Streptococcus mitis 
- Group A and B hemolytic Streptococcus 
- S. aureus 
 
Gram-negative 
- H. influenzae 
- Haemophilus parainfluenzae 
- C. pneumoniae 
- E. cloacae 
- Enterobacter aerogenes 
- E. coli 
- Serratia marcescens 
- Proteus mirabilis 
- A. baumanniia 
- A. lwoffii 
- Pseudomonas aeruginosa 
Total 
34 
18 
1 
1 
14 
 
58 
6 
21 
20 
2 
1 
1 
1 
1 
1 
1 
3 
92 
34 
18 
1 
1 
14 
 
58 
6 
21 
20 
2 
1 
1 
1 
1 
1 
1 
3 
92 
File TM et al. 
(2007) (11) 
Gram-positive 
- S. pneumoniae 
- S. aureus 
 
108 
68 
40 
 
103 
66 
37 
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Gram-negative 
- H. influenzae 
- C. pneumoniae 
- Mycoplasma pneumoniae 
139 
42 
51 
46 
134 
41 
49 
44 
El Moussaoui  
R et al. (2006) 
(12) 
Gram-positive 
- S. pneumoniae 
 
Gram-negative 
- H. influenzae 
- Moraxella catharrhalis 
- Haemophilus parainfluenzae 
- Influenza A or B 
- C. pneumoniae 
- Mycoplasma pneumoniae 
Unknown how 
the number of 
bacteria is 
distributed, 
but overall 
there were 45 
verified at the 
start of study 
Unknown how 
the number of 
bacteria is 
distributed, 
but overall 41 
were 
eradicated at 
the end of the 
study 
Dunbar LM et 
al. (2003) (13) 
Gram-positive 
- S. pneumoniae 
 
Gram-negative 
- H. influenzae 
- Haemophilus parainfluenzae 
- C. pneumoniae 
- Legionella pneumophila 
- Mycoplasma pneumoniae 
42 
42 
 
180 
27 
22 
38 
14 
79 
38 
38 
 
171 
25 
21 
36 
14 
75 
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Table 4 – Jadad score 
 
Study   
(year) 
1. Was the 
study  
described as 
randomised 
(this includes 
words such  
as randomly, 
random and 
randomisation)
? (+1 Point) 
2. Was the 
method used 
to generate 
the sequence 
of 
randomisatio
n described 
and 
appropriate 
(table of 
random 
numbers, 
computer-
generated)?  
(+1 Point) 
3. Was 
the study 
describe
d as 
double 
blind?  
(+1 
Point) 
4. Was the 
method of 
double 
blinding 
described 
and 
appropriat
e (identical 
placebo, 
active 
placebo, 
dummy)?  
(+1 Point) 
5. Was 
there a 
description 
of 
withdrawal
s and 
dropouts? 
(+1 Point) 
6. Deduct one 
point if the 
method used 
to generate 
the sequence 
of 
randomisatio
n was 
described and 
it was 
inappropriate 
(patients were 
allocated 
alternately, or 
according to 
date of birth, 
hospital 
number) 
7. Deduct 
one point if 
the study 
was 
described as 
double blind 
but the 
method of 
blinding was 
inappropriate 
(e.g., 
comparison 
of tablet vs. 
Injection 
with no 
double 
dummy). 
Total 
Uranga A 
et al. 
(2016) (8) 
1 1 0 0 1 0 0 3 
Zhao T et 
al. (2016) 
(9) 
1 1 0 0 1 0 0 3 
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Zhao X et 
al. (2014) 
(10) 
1 0 0 0 1 0 0 2 
File TM et 
al. (2007) 
(11) 
1 0 1 0 1 0 0 3 
El 
Moussaoi  
R et al. 
(2006) 
(12) 
1 0 1 1 1 0 0 4 
Dunbar 
LM et al. 
(2003) 
(13) 
1 0 1 1 1 0 0 4 
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Table 5 – Article overview of relapses, withdrawals and limitations 
 
Study (year) Relapses Patients withdrawals/ 
Mortality 
Limitations 
Uranga A et al. (2016) 
(8) 
Readmission by day 30 
was significantly more 
common in the control 
group than in the 
intervention group 9 vs. 
2, P = .02.  
 
Before randomisation, 
227 patients did not 
meet the selection 
criteria. Thirteen patients 
were later excluded for 
protocol violation.         In 
addition, 16 were 
unavailable for the late 
follow-up. For one of 
these patients no data 
was found, and it is not 
known if this is alive. 
First, almost 80% of the 
patients received 
quinolones. 
Second, because of the 
open design after day 5, 
there could have been an 
effect on physicians’ 
decisions concerning 
antibiotic duration in the 
control group.                
Third, patients with 
complications were 
excluded. 
Fourth, the study was 
conducted in 4 teaching 
hospitals in the Basque 
Country. 
Zhao T et al. (2016) (9) 1 patient in 750 mg 
group and 3 patients in 
500 mg group. P=0.6235. 
7 patients were unable to 
be evaluated due to 
incomplete data and 2 
did not meet the 
inclusion criteria. 
Another 21 patients did 
not meet the eligibility 
criteria or exclusion 
criteria.  
No death occurred in 
both groups. 
First, patients were 
diagnosed with mild to 
moderate CAP. Second, 
bacterial culture positive 
rate was low, 8.14% in 
750 mg group and 7.49% 
in 500 mg group.   
Third, the detection of 
atypical pathogens was 
not performed.   
Fourth, this was an open-
label design.  Fifth, 
relative stringent 
exclusion criteria were 
set.        Sixth, there was a 
difference of the 
evaluation time points. 
Zhao X et al. (2014) (10) Unknown 30 patients were 
excluded due to violation 
of inclusion/ exclusion 
criteria. 
First, late follow-up visit 
was missing. Second, the 
positivity of blood culture 
was too low to assess 
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microbiologic response.  
File TM et al. (2007) (11) Unknown 14 patients, including the 
two randomisation 
failures, were withdrawn 
prematurely from the 
study and 10 patients 
completed therapy but 
withdrew from follow-up. 
Adverse events were the 
main reason for 
premature 
discontinuation. An 
additional 3 patients 
were excluded as a result 
of poor visits compliance. 
A potential limitation of 
the study is that there 
was a trend towards 
sicker patients in the 7-
day group. 
El Moussaoui  
R et al. (2006) (12) 
Unknown Between enrolment and 
randomisation 19 
patients withdrew their 
consent for participation, 
41 did not meet the 
criteria for 
randomisation, and 5 
were not randomised for 
other reasons.  
Two were subsequently 
excluded because of 
protocol violations. 
First, there were more 
severe symptoms and a 
higher percentage of 
smokers in the 3-day 
treatment group. Second, 
only patients with mild to 
moderate- severe 
community acquired 
pneumonia who 
substantially improved 
after 3 days’ amoxicillin 
treatment.  Third, we 
excluded patients with a 
severe immunodeficiency. 
Fourth, our sample size 
was moderate. 
Dunbar LM et al. (2003) 
(13) 
4 patients, all of whom 
were in the 750-mg 
group, were classified as 
having relapses solely on 
the basis of clinical and 
radiographic criteria. 
6 patients were 
withdrawal.  
 
First, patients with a PSI 
score of >130 were 
excluded from the study.             
Second, there were a 
relatively large number of 
CAP cases attributed to 
M. pneumoniae, which is 
generally understood to 
have a less severe 
presentation. 
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